Sagar Panse, MD
Nephrology · Macon, GANPI 1033132212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $445,857 of the $541,865 with a category attached, or 82.3%. 37 manufacturers reported payments, led by AstraZeneca at 32.2% of the total. Reporting peaked in 2022 at $159,788 and has fallen 98.5% since, to $2,445 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 832 payments — averaging $651.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$174K
- Bayer$154K
- Johnson & Johnson$149K
- Vifor Pharma, Inc.$46K
- Janssen Scientific Affairs, LLC$6K
- Amgen$5K
- plus $7K from 31 others
Across 87 payments — averaging $5974.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$213K
- GSK$187K
- Bayer$91K
- Vertex$15K
- AstraZeneca$14K
What the payments were for
- Consulting fees$21,5554%
- Speaking & faculty fees$445,85782%
- Travel & lodging$57,38711%
- Food & beverage$16,7793%
- Education$2870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 247 | $174,250 |
| Bayer | 196 | $154,472 |
| Johnson & Johnson | 110 | $149,140 |
| Vifor Pharma, Inc. | 54 | $46,224 |
| Janssen Scientific Affairs, LLC | 6 | $5,818 |
| Amgen(2 entities) | 48 | $5,455 |
| Scpharmaceuticals Inc. | 4 | $3,248 |
| Aurinia Pharma U.S., Inc. | 24 | $455 |
| Otsuka America Pharmaceutical, Inc. | 16 | $408 |
| Novo Nordisk | 15 | $373 |
| Akebia Therapeutics Inc | 13 | $270 |
| Travere Therapeutics, Inc. | 28 | $257 |
| Valeritas, Inc. | 3 | $197 |
| Novartis | 9 | $181 |
| GSK | 10 | $164 |
| Merck | 7 | $106 |
| Ardelyx, Inc. | 5 | $105 |
| Fresenius USA Marketing, Inc. | 5 | $75 |
| Boehringer Ingelheim | 3 | $73 |
| Mallinckrodt Hospital Products Inc. | 2 | $62 |
| OPKO Pharmaceuticals, LLC | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Calliditas Therapeutics US Inc. | 3 | $57 |
| Pfizer | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Fresenius USA Manufacturing, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Medtronic | 1 | $29 |
| Amicus Therapeutics, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| Rockwell Medical, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$541,865 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 15 | $455,293 |
| FarxigaDapagliflozin Propanediol | 234 | $252,529 |
| KerendiaFinerenone | 169 | $197,577 |
| JardianceEmpagliflozin | 106 | $98,399 |
| LokelmaSodium Zirconium Cyclosilicate | 65 | $82,298 |
| JanuviaSitagliptin Phosphate | 35 | $54,019 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $46,197 |
| OzempicSemaglutide | 35 | $37,888 |
| AuryxiaFerric Citrate | 13 | $34,622 |
| RayaldeeCalcifediol | 18 | $25,847 |
| MounjaroTirzepatide | 11 | $18,084 |
| Sevelamer Carbonate | 86 | $11,514 |
| EntrestoSacubitril/Valsartan | 13 | $8,813 |
| DapagliflozinDapagliflozin Propanediol | 14 | $8,475 |
| Cinacalcet Hcl | 11 | $4,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $5,455 | $455,29315 claims |
| AstraZenecaFarxiga, Lokelma | $174,250 | $334,827299 claims |
| BayerKerendia | $154,472 | $197,577169 claims |
| Boehringer IngelheimJardiance | $73 | $98,399106 claims |
| MerckJanuvia | $106 | $54,01935 claims |
| Novo NordiskOzempic | $373 | $37,88835 claims |
| Akebia Therapeutics IncAuryxia | $270 | $34,62213 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $60 | $25,84718 claims |
| Lilly USA, LLCMounjaro | $37 | $18,08411 claims |
| NovartisEntresto | $181 | $8,81313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Macon
- Kimathi BlackwoodMacon$64K
- Reuben EllisMacon$27K
- Ahmad KabbaniMacon$16K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.